The stability of mRNA encoding IL-4 is increased in pulmonary tuberculosis, while stability of mRNA encoding the antagonistic splice variant, IL-4δ2, is not

被引:16
作者
Dheda, Keertan [1 ]
Chang, Jung-Su
Huggett, Jim F.
Kim, Louise U.
Johnson, Margaret A.
Zumla, Alimuddin
Rook, Graham A. W.
机构
[1] UCL & Royal Free Med Sch, Ctr Infect Dis & Int Hlth, London, England
[2] Royal Free Hosp NHS Trust, Dept Thorac & HIV Med, London W1T 4JF, England
[3] Univ Cape Town, Dept Med, Div Pulm, ZA-7925 Cape Town, South Africa
关键词
IL-4; IL-462; human; half-life; tuberculosis; mRNA;
D O I
10.1016/j.tube.2006.11.001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The prototype Th2 cytokine IL-4, and its competitive antagonist IL-4 delta 2, may be important determinants of outcome in human tuberculosis (TB). However, there are no data on how gene expression of these cytokines is regulated. To evaluate this the stability of IL-4 and IL-4 delta 2 mRNA after the addition of actinomycin-D, was evaluated in whole blood from subjects with pulmonary TB and uninfected healthy volunteers. The Th2/Th1 (IL-4/IFN-gamma) mRNA ratio in unstimulated cells in whole blood was significantly greater in TB subjects than in controls (p<0.05). The mRNA half-life of the agonist (IL-4), but not the antagonist (IL-4 delta 2), was significantly prolonged in subjects with TB compared to healthy volunteers (similar to 5-fold, p = 0.0016), and the IL-4/IL-4 delta 2 ratio was higher in TB patients compared to controls (p<0.05). The differential stability of the Th2 agonist, IL-4, compared to the antagonist IL-4 delta 2, represents a hitherto undescribed post-transcriptional regulatory mechanism that may modulate the polarisation of Th1 /Th2 responses in human TB. (C) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:237 / 241
页数:5
相关论文
共 32 条
[1]  
Atamas SP, 1996, J IMMUNOL, V156, P435
[2]  
Atamas SP, 1999, ARTHRITIS RHEUM, V42, P1168, DOI 10.1002/1529-0131(199906)42:6<1168::AID-ANR13>3.0.CO
[3]  
2-L
[4]   Acute cardiac transplant rejection is associated with low frequencies of interleukin-4 producing helper T-lymphocytes rather than with interleukin-4 promoter or splice variants [J].
Bijlsma, FJ ;
van Kuik, J ;
van Hoffen, E ;
de Jonge, N ;
Tilanus, MGJ ;
Gmelig-Meyling, FHJ ;
de Weger, RA .
HUMAN IMMUNOLOGY, 2002, 63 (04) :317-323
[5]   Altered IL-4 mRNA stability correlates with Th1 and Th2 bias and susceptibility to hypersensitivity pneumonitis in two inbred strains of mice [J].
Butler, NS ;
Monick, MM ;
Yarovinsky, TO ;
Powers, LS ;
Hunninghake, GW .
JOURNAL OF IMMUNOLOGY, 2002, 169 (07) :3700-3709
[6]   Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high evels of Th1 cytokines and the IL-4 antagonist IL-4δ2 [J].
Demissie, A ;
Abebe, M ;
Aseffa, A ;
Rook, G ;
Fletcher, H ;
Zumla, A ;
Weldingh, K ;
Brock, I ;
Andersen, P ;
Doherty, TM .
JOURNAL OF IMMUNOLOGY, 2004, 172 (11) :6938-6943
[7]   Validation of housekeeping genes for normalizing RNA expression in real-time PCR [J].
Dheda, K ;
Huggett, JF ;
Bustin, SA ;
Johnson, MA ;
Rook, G ;
Zumla, A .
BIOTECHNIQUES, 2004, 37 (01) :112-+
[8]   Expression of a novel cytokine, IL-4deltaf in HIV and HIV-tuberculosis co-infection [J].
Dheda, K ;
Chang, JS ;
Breen, RAM ;
Haddock, JA ;
Lipman, MC ;
Kim, LU ;
Huggett, JF ;
Johnson, MA ;
Rook, GAW ;
Zumla, A .
AIDS, 2005, 19 (15) :1601-1606
[9]   In vivo and in vitro studies of a novel cytokine, interleukin 4δ2, in pulmonary tuberculosis [J].
Dheda, K ;
Chang, JS ;
Breen, AM ;
Kim, LU ;
Haddock, JA ;
Huggett, JF ;
Johnson, MA ;
Rook, GAW ;
Zumla, A .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 172 (04) :501-508
[10]   Clinical and serological studies of tuberculosis patients in Argentina receiving immunotherapy with Mycobacterium vaccae (SRL 172) [J].
Dlugovitzky, D ;
Bottasso, O ;
Dominino, JC ;
Valentini, E ;
Hartopp, R ;
Singh, M ;
Stanford, C ;
Stanford, J .
RESPIRATORY MEDICINE, 1999, 93 (08) :557-562